Literature DB >> 24409072

Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer.

Xin Jiao1, Hong-Jun Lu1, Mi-Mi Zhai1, Zhi-Jun Tan1, Hai-Ning Zhi1, Xiao-Man Liu1, Chen-Hao Liu1, Da-Peng Zhang1.   

Abstract

AIM: To analyze the expression of kallikrein gene 10 (KLK10) in gastric cancer and to determine whether KLK10 has independent prognostic value in gastric cancer.
METHODS: We studied KLK10 expression in 80 histologically confirmed gastric cancer samples using real-time quantitative reverse transcription-PCR and hK10 expression using immunohistochemistry. Correlations with clinicopathological variables (lymph node metastasis, depth of invasion and histology) and with outcomes (disease-free survival and overall survival) during a median follow-up period of 31 mo were assessed. Gastric cancer tissues were then classified as KLK10 positive or negative.
RESULTS: KLK10 was found to be highly expressed in 57/80 (70%) of gastric cancer samples, while its expression was very low in normal gastric tissues. Positive relationships between KLK10 expression and lymph node metastasis (P = 0.048), depth of invasion (P = 0.034) and histology (P = 0.015) were observed. Univariate survival analysis revealed that gastric cancer patients with positive KLK10 expression had an increased risk for relapse/metastasis and death (P = 0.005 and 0.002, respectively). Cox multivariate analysis indicated that KLK10 was an independent prognostic indicator of disease-free survival and overall survival in patients with gastric cancer.
CONCLUSION: KLK10 expression is an independent biomarker of unfavorable prognosis in patients with gastric cancer.

Entities:  

Keywords:  Gastric cancer; Kallikrein gene 10; Prognostic biomarkers; Survival analysis

Mesh:

Substances:

Year:  2013        PMID: 24409072      PMCID: PMC3882418          DOI: 10.3748/wjg.v19.i48.9425

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Current status and progress in gastric cancer with liver metastasis.

Authors:  Jing Liu; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2011-02       Impact factor: 2.628

2.  Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14.

Authors:  Rithwik Ramachandran; Azza Eissa; Koichiro Mihara; Katerina Oikonomopoulou; Mahmoud Saifeddine; Bernard Renaux; Eleftherios Diamandis; Morley D Hollenberg
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

3.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Authors:  Ekaterina Olkhov-Mitsel; Theodorus Van der Kwast; Ken J Kron; Hilmi Ozcelik; Laurent Briollais; Christine Massey; Franz Recker; Maciej Kwiatkowski; Neil E Fleshner; Eleftherios P Diamandis; Alexandre R Zlotta; Bharati Bapat
Journal:  Epigenetics       Date:  2012-08-09       Impact factor: 4.528

4.  Human kallikrein 10: a novel tumor marker for ovarian carcinoma?

Authors:  L Y Luo; P Bunting; A Scorilas; E P Diamandis
Journal:  Clin Chim Acta       Date:  2001-04       Impact factor: 3.786

Review 5.  Human tissue kallikreins: a family of new cancer biomarkers.

Authors:  Eleftherios P Diamandis; George M Yousef
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

6.  Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.

Authors:  Carla A Borgoño; Linda Grass; Antoninus Soosaipillai; George M Yousef; Constantina D Petraki; David H C Howarth; Stefano Fracchioli; Dionyssios Katsaros; Eleftherios P Diamandis
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

7.  Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma.

Authors:  Maroulio Talieri; Eleftherios P Diamandis; Dimitrios Gourgiotis; Kostandina Mathioudaki; Andreas Scorilas
Journal:  Thromb Haemost       Date:  2004-01       Impact factor: 5.249

8.  Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

Authors:  Margaritis Avgeris; Georgia Papachristopoulou; Athanasios Polychronis; Andreas Scorilas
Journal:  Clin Proteomics       Date:  2011-05-31       Impact factor: 3.988

9.  Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.

Authors:  H Kim; A Scorilas; D Katsaros; G M Yousef; M Massobrio; S Fracchioli; R Piccinno; G Gordini; E P Diamandis
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

10.  The global burden of cancer: priorities for prevention.

Authors:  Michael J Thun; John Oliver DeLancey; Melissa M Center; Ahmedin Jemal; Elizabeth M Ward
Journal:  Carcinogenesis       Date:  2009-11-24       Impact factor: 4.944

View more
  8 in total

1.  Prospective quantitative gene expression analysis of kallikrein-related peptidase KLK10 as a diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Shwan Majid Ahmad; Basima Sadq Ahmed; Karzan Ghafur Khidhir; Heshu Sulaiman Rahman
Journal:  PeerJ       Date:  2022-05-31       Impact factor: 3.061

Review 2.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

3.  Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Xiaocong Geng; Yueyang Liu; Sandra Diersch; Matthias Kotzsch; Sabine Grill; Wilko Weichert; Marion Kiechle; Viktor Magdolen; Julia Dorn
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

4.  Urinary kallikrein 10 predicts the incurability of gastric cancer.

Authors:  Takaya Shimura; Masahide Ebi; Tomonori Yamada; Tamaki Yamada; Takahito Katano; Yu Nojiri; Hiroyasu Iwasaki; Satoshi Nomura; Noriyuki Hayashi; Yoshinori Mori; Hiromi Kataoka; Marsha A Moses; Takashi Joh
Journal:  Oncotarget       Date:  2017-04-25

5.  Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10.

Authors:  Mekdes Debela; Viktor Magdolen; Wolfram Bode; Hans Brandstetter; Peter Goettig
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

6.  Quantifying critical states of complex diseases using single-sample dynamic network biomarkers.

Authors:  Xiaoping Liu; Xiao Chang; Rui Liu; Xiangtian Yu; Luonan Chen; Kazuyuki Aihara
Journal:  PLoS Comput Biol       Date:  2017-07-05       Impact factor: 4.475

7.  Non-coding RNAs profiling in head and neck cancers.

Authors:  Daria Salyakina; Nicholas F Tsinoremas
Journal:  NPJ Genom Med       Date:  2016-01-13       Impact factor: 8.617

8.  KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study.

Authors:  Mustafa A El Sherbini; Amal A Mansour; Maha M Sallam; Emtiaz A Shaban; Zeinab A Shehab ElDin; Amr H El-Shalakany
Journal:  J Ovarian Res       Date:  2018-04-24       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.